Isoform-selective targeting of PI3K: time to consider new opportunities?
- 11 July 2023
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 44 (9) , 601-621
Abstract
No abstract availableKeywords
Funding Information
- Volkswagenstiftung
This publication has 89 references indexed in Scilit:
- Phosphatidylinositol-3-Kinase C2β and TRIM27 Function To Positively and Negatively Regulate IgE Receptor Activation of Mast CellsMolecular and Cellular Biology, 2012
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase InhibitorMolecular Cancer Therapeutics, 2012
- Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-KinasesScience Signaling, 2011
- Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of CancerJournal of Medicinal Chemistry, 2011
- Activity of any class IA PI3K isoform can sustain cell proliferation and survivalProceedings of the National Academy of Sciences, 2010
- The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitorsNature Chemical Biology, 2010
- Association of the PIK3C2G gene polymorphisms with type 2 DM in a Japanese populationBiochemical and Biophysical Research Communications, 2007
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- The N‐terminus of phosphoinositide 3‐kinase‐C2β regulates lipid kinase activity and binding to clathrinJournal of Cellular Physiology, 2005
- Insulin Activates the α Isoform of Class II Phosphoinositide 3-KinaseJournal of Biological Chemistry, 1999